![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Defence Therapeutics
Main (gene editing) focus: Novel methods for delivery of gene-editing systems
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:DTCFF)
Location: Vancouver, British Columbia, Canada
Website: https://defencetherapeutics.com/
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_DEFENCE1-27731-SR-logo_cf106e34bc_fcba320ae1.jpg)
Defence Therapeutics develops a proprietary platform called ACCUMTM, which enables precision delivery of vaccine antigens or drugs to target cells. The company recently announced strong in vitro results for the delivery of the CRISPR-Cas9 system using ACCUMTM technology. The company now seeks collaborations in the gene-editing space.